Harrow to acquire Melt Pharmaceuticals for $0.50/share; already owns 45%

HARROW, INC.

Harrow will pay $0.50 per share of Melt Common Stock for the remaining ~55% it does not already own.
Melt is a clinical-stage company developing MELT-300 for procedural sedation in cataract surgery.
Transaction approved by special committees of both boards, each receiving fairness opinions.
Harrow and Melt entered a Milestone Payment Agreement tied to regulatory and sales milestones.
Merger Sub will merge with and into Melt; Melt will survive as wholly owned subsidiary of Harrow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.